X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ACTAVIS (US) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   ACTAVIS
EQUITY SHARE DATA
    NOVARTIS
Mar-16
ACTAVIS
Dec-14
NOVARTIS/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs98217,478-   
Low Rs55610,661-   
Sales per share (Unadj.) Rs252.93,147.4-  
Earnings per share (Unadj.) Rs62.1-392.8-  
Cash flow per share (Unadj.) Rs63.3288.8-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.66,826.5-  
Shares outstanding (eoy) m31.96265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.04.5 68.0%   
Avg P/E ratio x12.4-35.8 -34.5%  
P/CF ratio (eoy) x12.248.7 24.9%  
Price / Book Value ratio x2.12.1 102.6%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,5803,741,152 0.7%   
No. of employees `0000.821.6 3.5%   
Total wages/salary Rs m1,8010-   
Avg. sales/employee Rs Th10,748.938,744.6 27.7%   
Avg. wages/employee Rs Th2,395.20-   
Avg. net profit/employee Rs Th2,641.1-4,834.9 -54.6%   
INCOME DATA
Net Sales Rs m8,083836,882 1.0%  
Other income Rs m829-2,089 -39.7%   
Total revenues Rs m8,913834,794 1.1%   
Gross profit Rs m234107,509 0.2%  
Depreciation Rs m37181,216 0.0%   
Interest Rs m226,397 0.0%   
Profit before tax Rs m1,025-102,192 -1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,696-7,496 -22.6%   
Tax Rs m752-5,254 -14.3%   
Profit after tax Rs m1,986-104,434 -1.9%  
Gross profit margin %2.912.8 22.6%  
Effective tax rate %73.45.1 1,426.9%   
Net profit margin %24.6-12.5 -196.9%  
BALANCE SHEET DATA
Current assets Rs m12,678440,930 2.9%   
Current liabilities Rs m2,433321,567 0.8%   
Net working cap to sales %126.714.3 888.6%  
Current ratio x5.21.4 380.0%  
Inventory Days Days3358 56.4%  
Debtors Days Days2266 33.9%  
Net fixed assets Rs m69102,192 0.1%   
Share capital Rs m1600-   
"Free" reserves Rs m11,4600-   
Net worth Rs m11,6211,815,167 0.6%   
Long term debt Rs m0951,183 0.0%   
Total assets Rs m14,4003,326,604 0.4%  
Interest coverage x570.5-2.9 -19,868.6%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.60.3 223.1%   
Return on assets %13.8-2.3 -588.5%  
Return on equity %17.1-5.8 -297.0%  
Return on capital %23.6-3.0 -783.0%  
Exports to sales %0.70-   
Imports to sales %18.60-   
Net fx Rs m-1,6350-   
CASH FLOW
From Operations Rs m2,531143,709 1.8%  
From Investments Rs m-8,270-344,094 2.4%  
From Financial Activity Rs m-386193,331 -0.2%  
Net Cashflow Rs m-6,125-7,054 86.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.07 Rs / USD

Compare NOVARTIS With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: WYETH LTD  SHASUN PHARMA  NATCO PHARMA  TORRENT PHARMA  ALEMBIC LTD  



Today's Market

Indian Indices Trade Marginally Higher; Pharma Sector Up 2.4%(11:30 am)

Stock markets in India are presently trading near the dotted line with positive bias. Sectoral indices are trading on a mixed note with stocks in the healthcare sector.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 24, 2017 12:13 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS